Barclays
ANRO icon

Barclays’s Alto Neuroscience ANRO Stock Holding History

Barclays’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$563K Sell
25,036
-5,356
-18% -$99.3K ﹤0.01% 3127
2025
Q4 		$541K Buy
30,392
+30,350
+72,262% +$382K ﹤0.01% 3798
2025
Q3 		$169 Buy
42
+41
+4,100% +$136 ﹤0.01% 5248
2025
Q2 		$2 Sell
1
-22,507
-100% -$53.6K ﹤0.01% 5192
2025
Q1 		$48.6K Sell
22,508
-17,299
-43% -$61.9K ﹤0.01% 4617
2024
Q4 		$168K Buy
39,807
+10,208
+34% +$63.7K ﹤0.01% 4383
2024
Q3 		$339K Buy
29,599
+26,556
+873% +$325K ﹤0.01% 4013
2024
Q2 		$32.5K Sell
3,043
-2,861
-48% -$37.2K ﹤0.01% 4345
2024
Q1 		$90.6K Buy
+5,904
New +$92.4K ﹤0.01% 4465

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's ANRO Position: Q1 2026 in Review

Barclays reduced its Alto Neuroscience (ANRO) stake by 18% in Q1 2026, selling an estimated $99.3K and leaving 25,036 shares worth $563K. The position accounts for ﹤0.01% of the portfolio, ranked #3127.

Barclays first reported a position in ANRO in Q1 2024 and has held it in 9 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Barclays held 25,036 shares of Alto Neuroscience worth $563K as of Q1 2026.
  • Barclays sold 5,356 Alto Neuroscience shares in Q1 2026, an estimated $99.3K.
  • Alto Neuroscience made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3127 holding.
  • Barclays first reported a position in Alto Neuroscience in Q1 2024 and has held it in 9 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.